Metabolic Dysfunction - Associated Steatohepatitis (MASH) treatment

Search documents
MetaVia to Present at Upcoming Investor and Industry Conferences
Prnewswire· 2025-08-26 12:31
Core Insights - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing two key drug candidates: DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [4] Company Overview - MetaVia is developing DA-1726, a novel oxyntomodulin (OXM) analogue that acts as a dual agonist for glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), showing potential for superior weight loss and glucose control compared to selective GLP1R agonists [4] - DA-1726 demonstrated best-in-class potential in a Phase 1 multiple ascending dose trial, indicating effectiveness in weight loss, glucose control, and waist reduction [4] - DA-1241 is a G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of gut peptides GLP-1, GIP, and PYY, showing positive effects on liver inflammation, lipid metabolism, and glucose metabolism in pre-clinical studies [4] - In a Phase 2a clinical study, DA-1241 exhibited direct hepatic action alongside glucose-lowering effects [4] Upcoming Events - MetaVia will participate in several upcoming conferences, including: - Wells Fargo Healthcare Conference from September 3-5, where CEO Hyung Heon Kim will attend [7] - H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, featuring a fireside chat and an on-demand presentation available from September 5 [7] - Obesity Science & Innovation 2025 Congress on September 16-17, where Mr. Kim will present an overview focusing on DA-1726 [7] - Fierce Biotech Week from October 7-9, with Mr. Kim's attendance [7]
MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient
Prnewswire· 2025-08-06 12:31
Core Insights - MetaVia Inc. has extended the Phase 1 clinical trial of DA-1726 from 4 weeks to 8 weeks to assess early efficacy, patient safety, and tolerability with longer-term exposure [1][2] - Top-line data from the extended trial is expected in the fourth quarter of 2025 [1] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity treatment and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [6] - DA-1726 is a novel oxyntomodulin (OXM) analogue that acts as a dual agonist for GLP-1 and glucagon receptors, potentially leading to superior weight loss compared to selective GLP-1 agonists [4][6] Clinical Trial Details - The Phase 1 trial is a randomized, double-blind, placebo-controlled study involving healthy adults with a BMI between 30 – 45 kg/m2 [2] - The trial's primary endpoint is to assess the safety and tolerability of DA-1726, while secondary endpoints include pharmacokinetics and exploratory endpoints focus on metabolic and cardiac parameters [2][5] Drug Efficacy and Safety - Previous data from the 32 mg dose of DA-1726 indicated a mean weight loss of 4.3% and a maximum of 6.3% by Day 26, with 83% of patients experiencing early satiety [2][5] - DA-1726 demonstrated a favorable safety profile, with a mild, transient gastrointestinal profile, and a differentiated tolerability compared to existing GLP-1 therapies [2][4] Future Outlook - The extension of the trial aims to provide more robust data that may position DA-1726 more strongly against current treatments and those in late-stage clinical trials [2] - The company anticipates that the results from the extended cohort will further validate DA-1726's longer-term safety and efficacy [2]